Although there is no evidence for detection of this mechanism in PD, recent studies on EVs present a promising PD therapy based on antisense oligonucleotide (ASO)-based gene therapy to reduce α-synuclein production [53]. The gene discussed is SNCA; the disease is Parkinson disease.